Literature DB >> 2814366

Expression of heterozygous lpr gene in MRL mice. I. Defective T-cell reactivity and polyclonal B-cell activation.

H Carlsten1, A Tarkowski.   

Abstract

The presence of the homozygous lpr gene (lpr/lpr) in MRL mice has been regarded as mandatory for the development of the early onset of lupus disease, T-cell dysfunction, and polyclonal B-cell activation. Congeneic MRL mice lacking the lpr gene (MRL +/+) display neither the lupus disease nor the immunological abnormalities within the first year of life. In this study we examined the cellular functions of MRL mice heterozygous at the lpr locus. The results indicate that MRL mice heterozygous at the lpr locus display intermediate delayed-type hypersensitivity compared with homozygous lpr/lpr mice on the one hand and congeneic +/+ mice on the other. Furthermore, proliferative responses to concanavalin A, measured by uptake of [3H]thymidine, were significantly lower in MRL mice heterozygous at the lpr locus than in +/+ mice, but significantly higher than in homozygous MRL lpr/lpr mice. Polyclonal B-cell activation, assessed by measurement of frequencies of IgG-secreting spleen cells, a prominent feature in MRL lpr/lpr mice, was significantly lower in lpr/+ mice and totally absent in +/+ mice. Furthermore, spleen cells spontaneously secreting auto-antibodies were found in large numbers in MRL lpr/lpr mice and in considerably lower but still significant numbers in heterozygous MRL +/lpr mice. In contrast, spleen cells from matched MRL +/+ mice did not display any spontaneous autoantibody production. Taken together, these data provide evidence for immunomodulatory properties of the heterozygous lpr gene.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2814366     DOI: 10.1111/j.1365-3083.1989.tb02450.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  8 in total

Review 1.  Cryoglobulins and the immunopathological manifestations of autoimmune disease.

Authors:  A M Denman
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

2.  Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS).

Authors:  A Katzav; Y Kloog; A D Korczyn; H Niv; D M Karussis; N Wang; R Rabinowitz; M Blank; Y Shoenfeld; J Chapman
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

3.  Differential effects of captopril and enalapril, two angiotensin converting enzyme inhibitors, on immune reactivity in experimental lupus disease.

Authors:  A Tarkowski; H Carlsten; H Herlitz; G Westberg
Journal:  Agents Actions       Date:  1990-08

4.  Purine receptor antagonist modulates serology and affective behaviors in lupus-prone mice: evidence of autoimmune-induced pain?

Authors:  David A Ballok; Boris Sakic
Journal:  Brain Behav Immun       Date:  2008-06-14       Impact factor: 7.217

5.  The apoptosis-1/Fas protein in human systemic lupus erythematosus.

Authors:  E Mysler; P Bini; J Drappa; P Ramos; S M Friedman; P H Krammer; K B Elkon
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

6.  Significant role of Fas ligand-binding but defective Fas receptor (CD95) in lymph node hyperplasia composed of abnormal double-negative T cells.

Authors:  Akio Matsuzawa; Motomu Shimizu; Yasutaka Takeda; Hisashi Nagase; Kazutoshi Sayama; Mikio Kimura
Journal:  Immunology       Date:  2002-08       Impact factor: 7.397

7.  The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms.

Authors:  K Takeda; G Dennert
Journal:  J Exp Med       Date:  1993-01-01       Impact factor: 14.307

8.  Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci.

Authors:  M L Watson; J K Rao; G S Gilkeson; P Ruiz; E M Eicher; D S Pisetsky; A Matsuzawa; J M Rochelle; M F Seldin
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.